title: Effect of LMO2 protein expression on survival in chronic myeloid leukemia patients treated with imatinib mesylate.
abstract: LIM domain only-2 (LMO2) is an important regulator of hematopoietic stem cell development. LMO2 protein is expressed in all three hematopoietic lineages precursors of the hematopoietic system, and its expression has been shown to decrease gradually during differentiation. Chronic myeloid leukemia (CML) is a malignant clonal myeloproliferative disorder in which the terminal differentiation is not altered until the appearance of an accelerated or blast phase. We examined whether LMO2 protein expression can predict outcome CML patients undergoing tyrosine kinase inhibitor therapy, imatinib mesylate (IM). Immunohistochemistry on bone marrow biopsy material for LMO2 protein was performed in 47 CML patients. We report that the LMO2 protein expression is correlated with improved hematologic remission and overall survival in the CML patients treated with IM. The immunohistologic analysis of LMO2 protein expression may become a predictive factor for anticipating the treatment responses of CML patients.
authors.affiliation: School of Medicine, Department of Haematology, Karadeniz Technical University, Trabzon 61080, Turkey. mesonmez@yahoo.com
authors.forename: Mehmet
authors.initials: M
authors.lastname: Sonmez
authors.forename: Tulin
authors.initials: T
authors.lastname: Akagun
authors.forename: Umit
authors.initials: U
authors.lastname: Cobanoglu
authors.forename: Murat
authors.initials: M
authors.lastname: Topbas
authors.forename: Nergiz
authors.initials: N
authors.lastname: Erkut
authors.forename: Mustafa
authors.initials: M
authors.lastname: Yilmaz
authors.forename: Ercument
authors.initials: E
authors.lastname: Ovali
authors.forename: Serdar Bedii
authors.initials: SB
authors.lastname: Omay
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D004268:DNA-Binding Proteins / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D060588:LIM Domain Proteins; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism*; D008297:Male; D008667:Metalloproteins / Q000096:biosynthesis*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011518:Proto-Oncogene Proteins / Q000096:biosynthesis; D011743:Pyrimidines / Q000627:therapeutic use*; D015996:Survival Rate; D055815:Young Adult
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000970:Antineoplastic Agents; D001549:Benzamides; D004268:DNA-Binding Proteins; D060588:LIM Domain Proteins; C085117:LMO2 protein, human; D008667:Metalloproteins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011518:Proto-Oncogene Proteins; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases